Efficacy and safety of systemic spironolactone for acne in female patients in Sulaymaniyah teaching center of dermatology

Soma Khasrow  Abdullah; Mohammed Yousef Saeed  Jaff

doi:10.56056/amj.2024.285

Authors

Soma Khasrow Abdullah KHCMS Dermatology trainee, Shahid Jabar Dermatological Teaching Center, Sulaimani Directorate of Health, Sulaimaniyah, Iraq
Mohammed Yousef Saeed Jaff Assistant Professor of dermatology, Department of Medicine, College of Medicine, University of Sulaimani, Sulaimaniyah, Iraq

DOI:

https://doi.org/10.56056/amj.2024.285

Keywords:

Acne, Female, Hormonal acne, Post-adolescent acne, Spironolactone

Abstract

Background and objectives: Acne vulgaris is a common disease in which hormone plays a role in its pathogenesis. Spironolactone, an androgen receptor blocker is used to treat acne. This study aims to evaluate the efficacy and safety of systemic spironolactone for acne in female patients in our local area.

Methods: Open-label therapeutic trial study performed in the Sulaymaniyah teaching center of dermatology between 1/2/2022 - 1/9/2022, on a total of 47 patients aged 12-38 years old. Patients were divided into two groups in regard to age. Hormonal profile was assessed for all the patients. The 4-grade European classification system was used to classify the acne severity. Spironolactone 100 mg once daily at morning was given to them with follow up monthly for 3 months. Clinical response of the drug was assessed through a decrease in the number of the lesions. Signs and symptoms of the side effects were checked monthly.

Results: In a total of 47 patients, 22 patients were ? 25 years and 25 patients were >25 years. A significant difference was recorded in the response rate among the patients' ages and hormonal status of them as 83.3%, 61.1% and 50% of the complete response was in those who were >25 years old and had abnormal testosterone and DHEA-s levels respectively. 100% of non-responder patients were below 25 years old with normal hormonal levels. 55.32% of the patients had no side-effect and menstrual irregularity was the most commonly reported side effect.

Conclusion: Spironolactone is statistically considered an effective and safe line for the treatment of acne vulgaris particularly for acne in female over 25 with abnormal hormonal levels.

Downloads

Download data is not yet available.

References

Cunliffe WJ And Simpson NB. Disorder of the Sebaceous Glands. In: Rook's Text Book of Dermatology, Burns T, Breathnach S, Cox N, Griffiths C. Vol 2, 7th ed. Blackwell Scientific Publication, 2004; 43: 1927-84.

Odom RB, James W, Timetly BG. Acne. In: Andrews Disease of the Skin, Clinical Dermatology, 9th ed. WB Sounder Company Philadelphia 2000; 13: 284-306.

James W. Acne. N Engl J Med. 2005; 352(14):1463-72.

Collier C, Harper J, Cantrell W, et al. The prevalence of acne in adults 20 years and older. J Am Acad Dermatol. 2008; 58:56-59.

Goulden V, Clark S, Cunliffe W. Post-adolescent acne: a review of clinical features. Br J Dermatol. 1997; 136:66-70.

Haider A, Shaw JC. Treatment of acne vulgaris. JAMA Dermatol. 2004; 292(6):726-35.

Hunter JAA, Savin JA, Dahl MV. Sebaceous and Sweat Gland Disorder. In: Clinical Dermatology, 3rd ed., Blackwell Publishing Company 2002; 21:148-62.

Zaenglein AL, Pathy AL, Schlosser BJ. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016; 74:945-73.

Karch AM. Lippincott's Nursing Drug Guide. Lippincott William and Wilkins 2003; 522-3.

Habif TP. Acne, Rosacea and Related Disorder. In: Clinical Dermatology, A color Guide to Diagnosis and Therapy, 4th ed. Mosby 2004; 7: 162-94.

Nast A, Dreno B, Bettoli V, et al. European evidence based (S3) guideline for the treatment of acne - update 2016 - short version. J Eur Acad Dermatol Venereol. 2016; 30: 1261-8.

Plovanich M, Weng QY, Mostaghimi A. Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for Acne. JAMA Dermatol. 2015; 151(9):941-4.

Koo JY, Smith LL. Physiological aspect of acne. Pediatr Dermatol. 1991; 8:185-8.

Barbieri JS, Spaccarelli N, Margolis DJ, et al. Approaches to limit systemic antibiotic use in acne: systemic alternatives, emerging topical therapies, dietary modification, and laser and light-based treatments. J Am Acad Dermatol. 2019; 80(2): 538-49.

Guzman AK, Barbieri JS. Comparative analysis of prescribing patterns of tetracycline class antibiotics and spironolactone between advanced practice providers and physicians in the treatment of acne vulgaris. J Am Acad Dermatol.2020; 06:044.

Ebede TL, Arch EL, Berson D. Hormonal treatment of acne in women. J Clin Aesthet Dermatol. 2009; 2(12):16-22.

Charny JW, Choi JK, James WD. Spironolactone for the treatment of acne in women, a retrospective study of 110 patients. Int J Womens Dermatol. 2017; 3: 111-5.

Roberts EE, Nowsheen S, Davis DMR, et al. Use of spironolactone to treat acne in adolescent females. Pediatr Dermatol. 2020; 00:1–5.

Roberts EE, Nowsheen S, Davis MDP, et al. Treatment of acne with spironolactone: a retrospective review of 395 adult patients at Mayo Clinic, 2007-2017. J Eur Acad Dermatol Venereol. 2020; 34:2106-10.

E. Sharquie Khalifa. Therapeutic Evaluation of Spironolactone and Finasteride in the Treatment of Acne Vulgaris. IPMJ. 2007; 6 (3): 206-10.

Grandhi R, Alikhan A. Spironolactone for the treatment of acne: a 4-year retrospective study. Dermatology. 2017; 233:141-4.

Burke BM, Cunliffe WJ. Oral spironolactone therapy for female patients with acne, hirsutism or androgenetic alopecia. Br J Dermatol. 1985; 112: 124-5.